Analysts See $-0.35 EPS for Iovance Biotherapeutics (IOVA); Psivida (PSDV) Sellers Increased By 3.63% Their Shorts

October 12, 2017 - By test

Psivida Corporation (NASDAQ:PSDV) had an increase of 3.63% in short interest. PSDV’s SI was 1.16M shares in October as released by FINRA. Its up 3.63% from 1.12M shares previously. With 207,600 avg volume, 6 days are for Psivida Corporation (NASDAQ:PSDV)’s short sellers to cover PSDV’s short positions. The SI to Psivida Corporation’s float is 4.2%. The stock decreased 1.61% or $0.02 during the last trading session, reaching $1.22. About 932,761 shares traded or 62.03% up from the average. pSivida Corp. (NASDAQ:PSDV) has declined 20.28% since October 12, 2016 and is downtrending. It has underperformed by 36.98% the S&P500.

Analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to report $-0.35 EPS on November, 3.They anticipate $0.03 EPS change or 9.37% from last quarter’s $-0.32 EPS. After having $-0.37 EPS previously, Iovance Biotherapeutics Inc’s analysts see -5.41% EPS growth. The stock decreased 1.34% or $0.1 during the last trading session, reaching $7.35. About 507,258 shares traded. Iovance Biotherapeutics Inc (NASDAQ:IOVA) has 0.00% since October 12, 2016 and is . It has underperformed by 16.70% the S&P500.




Investors sentiment increased to 1.23 in 2017 Q2. Its up 0.23, from 1 in 2017Q1. It is positive, as 4 investors sold pSivida Corp. shares while 9 reduced holdings. 7 funds opened positions while 9 raised stakes. 5.76 million shares or 26.29% less from 7.81 million shares in 2017Q1 were reported. Private Advisor Gp Limited holds 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV) for 30,200 shares. Susquehanna Gru Llp, Pennsylvania-based fund reported 53,453 shares. 71,800 were reported by Finemark Bankshares And. The Illinois-based Grp One Trading Limited Partnership has invested 0% in pSivida Corp. (NASDAQ:PSDV). Creative Planning holds 0% or 35,000 shares. Blackrock, a New York-based fund reported 124,330 shares. Morgan Stanley invested in 274,333 shares or 0% of the stock. Renaissance Technologies Ltd Com accumulated 1.37 million shares. 1.15 million are owned by Perceptive Advisors Limited Liability Com. Bard Associates Incorporated reported 0.07% in pSivida Corp. (NASDAQ:PSDV). Pnc Fincl Ser Group Inc Inc Inc holds 0% in pSivida Corp. (NASDAQ:PSDV) or 25,800 shares. Matrix Asset Advsrs New York holds 26,500 shares. Art Advsr Ltd Liability Com owns 24,226 shares. Moreover, Advisers Limited Liability has 0% invested in pSivida Corp. (NASDAQ:PSDV) for 10,000 shares. Bridgeway Cap Incorporated stated it has 133,900 shares or 0% of all its holdings.

Since June 14, 2017, it had 1 insider purchase, and 0 selling transactions for $99,962 activity. Shares for $99,962 were bought by Lurker Nancy.

Among 5 analysts covering pSivida (NASDAQ:PSDV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. pSivida had 12 analyst reports since October 15, 2015 according to SRatingsIntel. As per Wednesday, October 11, the company rating was maintained by H.C. Wainwright. The company was maintained on Wednesday, June 14 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $500 target in Tuesday, July 11 report. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, September 12. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) on Friday, June 23 with “Buy” rating. As per Wednesday, September 27, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by Northland Capital on Wednesday, June 14. The firm earned “Buy” rating on Tuesday, May 30 by H.C. Wainwright. The stock of pSivida Corp. (NASDAQ:PSDV) earned “Buy” rating by FBR Capital on Tuesday, June 13. The company was initiated on Thursday, October 15 by FBR Capital.

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The company has market cap of $47.96 million. The Firm operates through the biotechnology sector segment. It currently has negative earnings. The Firm has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema , its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: